Shilpa Medicare partners with Swiss firm NXI Therapeutics to develop NCEShilpa Medicare partners with Swiss firm NXI Therapeutics to develop NCE

Introduction

Leading pharmaceutical and CDMO company partnered with NXI Therapeutics AG for development and commercial manufacturing of a novel therapy targeting autoimmune and alloimmune disorders.

Also Read: GE Power India rallies 20% upper circuit post-Q3; here’s what the figures show

Share price movement of Shilpa Medicare

On February 13, 2026, Shilpa Medicare Ltd opened at ₹321.00, up 1.18% from its previous close of ₹323.30. The stock reached a high of ₹335.55 (3.79%) and a low of ₹315.60 (-2.34%). By 3:31 PM, it traded at ₹327.10, a 1.18% increase, with a market cap of ₹6,397.48 crore.

Shilpa Medicare Partners with NXI

Shilpa Medicare Limited has entered into a strategic partnership with NXI Therapeutics AG, Switzerland, for development and commercial manufacturing of a novel therapy targeting autoimmune and alloimmune disorders.

Under the agreement, Shilpa Medicare will provide CMC development, process scale-up, GMP clinical supply, and commercial manufacturing support, covering early development through commercialization for the new chemical entity.

This marks Shilpa’s third major international mandate in recent months, highlighting growing demand from Western biotech companies for its integrated R&D capabilities and advanced GMP manufacturing infrastructure.

Stock performance of Shilpa Medicare for period of 1 week, 6 months, and 1 year

Shilpa Medicare Ltd delivered a 2.30% return over the past week, declined 28.9% in the past 6 months, and fell 4.96% over the past 1 year.

Also Read: Bondada Engineering jumps 4% after signing strategic MOU for green-powered data centres

Shareholding pattern of Shilpa Medicare

Particulars	Dec 2025	Sep 2025	Jun 2025
Promoter	40.10%	44.20%	44.20%
FII	11%	10.90%	11.20%
DII	8%	8%	8%
Public	40.60%	37.20%	37.10%

About Shilpa Medicare

Shilpa Medicare Limited (SHILPAMED) is a global pharmaceutical and integrated CDMO offering end-to-end solutions across small molecules, biologics, and complex therapeutics for development and commercialization.

Stay Ahead with the Latest Stock Market Updates – Click Here

Disclaimer: The above article is written for educational purposes, and the companies’ data mentioned in the article may change with respect to time. The securities quoted are exemplary and are not recommendatory.

FAQs